BIO-Europe Spring® 2016: Where can Adocia fit in the diabetes market?

May 12, 2016
Dr. Remi Soula, co-founder and director of business development and intellectual property at Adocia, chats with Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about being a smaller business in the highly competitive diabetes space. He explains more about Adocia's business model, the company's pipeline technology, and their ongoing partnership with diabetes giant, Eli Lilly. Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a fast-acting formulation of human insulin (HinsBet U100), and a combination of slow-acting insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing a concentrated formulation of human insulin (HinsBet U500).
Previous Article
How drug development is like your diet
How drug development is like your diet

If you’re like me, you read the dailies. Companies run the gamut from riding high and plump on investment i...

Next Video
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeu...